← Back to Screener
Adaptive Biotechnologies Corporation Common Stock (ADPT)
Price$16.90
Value ScoreD
Growth ScoreB
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)-21.96%
Price vs S&P 500 (4W)22.38%
VGM Score59.39
Market Capitalization$2.70B
All Metrics
Book Value / Share (Quarterly)$1.35
P/TBV (Annual)11.42x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)14.34%
Cash Flow / Share (Quarterly)$-0.18
Price vs S&P 500 (YTD)-4.09%
Gross Margin (TTM)75.26%
Net Profit Margin (TTM)-16.82%
EPS (TTM)$-0.33
10-Day Avg Trading Volume2.08M
EPS Excl Extra (TTM)$-0.33
Revenue Growth (5Y)23.00%
EPS (Annual)$-0.39
ROI (Annual)-17.00%
Gross Margin (Annual)74.24%
Net Profit Margin (5Y Avg)-97.06%
Cash / Share (Quarterly)$1.37
Revenue Growth QoQ (YoY)35.14%
ROA (Last FY)-11.60%
Revenue Growth TTM (YoY)55.87%
EBITD / Share (TTM)$-0.23
ROE (5Y Avg)-51.27%
Operating Margin (TTM)-15.82%
Cash Flow / Share (Annual)$-0.32
P/B Ratio12.50x
P/B Ratio (Quarterly)9.88x
Net Income / Employee (Annual)$-95,400
EV / Revenue (TTM)9.34x
Net Interest Coverage (TTM)-24.47x
ROA (TTM)-9.91%
EPS Incl Extra (Annual)$-0.39
Current Ratio (Annual)3.34x
Quick Ratio (Quarterly)3.08x
3-Month Avg Trading Volume1.93M
52-Week Price Return71.23%
Revenue / Employee (TTM)$473,400
Tangible BV / Share (Quarterly)$1.35
P/S Ratio (Annual)9.77x
Asset Turnover (Annual)0.54x
52-Week High$20.76
Operating Margin (5Y Avg)-97.65%
EPS Excl Extra (Annual)$-0.39
CapEx CAGR (5Y)-30.91%
Tangible BV CAGR (5Y)-21.61%
26-Week Price Return-14.04%
Quick Ratio (Annual)3.10x
13-Week Price Return6.09%
Total Debt / Equity (Annual)0.60x
Current Ratio (Quarterly)3.35x
Enterprise Value$2.76B
Revenue / Share Growth (5Y)19.47%
Asset Turnover (TTM)0.59x
Book Value / Share Growth (5Y)-23.42%
Revenue / Employee (Annual)$443,900
Inventory Turnover (Annual)7.82x
Pretax Margin (Annual)-21.47%
Cash / Share (Annual)$1.48
3-Month Return Std Dev74.78%
Gross Margin (5Y Avg)65.28%
Net Income / Employee (TTM)$-79,600
ROE (Last FY)-27.19%
Net Interest Coverage (Annual)-16.02x
EPS Basic Excl Extra (Annual)$-0.39
Receivables Turnover (TTM)6.43x
Total Debt / Equity (Quarterly)0.60x
EPS Incl Extra (TTM)$-0.33
Receivables Turnover (Annual)6.01x
ROI (TTM)-14.76%
P/S Ratio (TTM)9.16x
Pretax Margin (5Y Avg)-97.09%
Revenue / Share (Annual)$1.83
Tangible BV / Share (Annual)$1.41
Price vs S&P 500 (52W)46.86%
Year-to-Date Return4.06%
5-Day Price Return10.97%
EPS Normalized (Annual)$-0.39
ROA (5Y Avg)-24.21%
Net Profit Margin (Annual)-21.48%
Month-to-Date Return11.55%
Cash Flow / Share (TTM)$-1.21
EBITD / Share (Annual)$-0.30
Operating Margin (Annual)-20.62%
LT Debt / Equity (Annual)0.58x
ROI (5Y Avg)-38.64%
LT Debt / Equity (Quarterly)0.58x
EPS Basic Excl Extra (TTM)$-0.33
P/TBV (Quarterly)9.94x
P/B Ratio (Annual)11.33x
Inventory Turnover (TTM)7.35x
Pretax Margin (TTM)-16.80%
Book Value / Share (Annual)$1.42
Price vs S&P 500 (13W)-2.17%
Beta2.13x
P/FCF (Annual)13.93x
Revenue / Share (TTM)$1.90
ROE (TTM)-24.26%
52-Week Low$9.78
vGradeD
gGradeB
mGradeB
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.12est. -0.16
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.21
4.21
4.21
4.21
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ADPTAdaptive Biotechnologies Corporation Common Stock | D | B | B | $16.90 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
Adaptive Biotechnologies develops diagnostic tests that leverage the adaptive immune system to detect and monitor cancer. The company's flagship product, clonoSEQ, is FDA-authorized for minimal residual disease monitoring in patients with multiple myeloma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia. The test is also available as a CLIA-validated service for other lymphoid malignancies, including diffuse large B-cell lymphoma.